With a mission to bring novel therapies to patients worldwide, VectorY combines the therapeutic potential of antibodies and gene therapy to overcome limitations and focus on disease areas with high unmet medical needs. Founded in August 2020, VectorY is based in the Amsterdam Science Park and specializes in vectorized antibodies for CNS and somatic disorders, particularly muscle diseases. Their proprietary platform utilizes advanced vector technologies, enabling scalable manufacturing processes and the development of long-lasting therapeutic solutions. With state-of-the-art R&D and manufacturing facilities in Amsterdam, VectorY is poised to deliver clinical and commercial supply through their multi-product GMP facility, capable of suspension-based AAV viral vector manufacturing of up to 2000L.